(-)(1Ξ:3R)-3-methyl-cyclohexane-carboxylic acid-(1)-amide | 13747-97-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (-)(1Ξ:3R)-3-methyl-cyclohexane-carboxylic acid-(1)-amide
• 英文别名: (-)(1Ξ:3R)-3-Methyl-cyclohexan-carbonsaeure-(1)-amid；(3R)-3-methylcyclohexane-1-carboxamide
• CAS: 13747-97-2
• 化学式: C₈H₁₅NO
• 分子量: 141.213
• InChiKey: ZHJFHMFTTQIXDF-ULUSZKPHSA-N

物化性质

• 沸点：
  281.9±7.0 °C(Predicted)
• 密度：
  0.974±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (-)(1Ξ:3R)-3-methyl-cyclohexane-carboxylic acid-(1)-chloride 在 氨 作用下， 生成 (-)(1Ξ:3R)-3-methyl-cyclohexane-carboxylic acid-(1)-amide
  参考文献：
  名称：

  Reliability of the time trade-off technique of utility assessment in patients with retinal disease

  摘要：

  Background: Studies in medical fields other than ophthalmology have given conflicting results regarding the reliability of the time trade-off technique of utility assessment. We performed a study to determine the test-retest reliability of the time trade-off technique for assessing utilities in patients with ocular diseases of the retina and to investigate possible factors associated with differences in utility over time.Methods: Patients referred to the retina service of a tertiary care hospital in eastern Canada were eligible for the initial interview if they had best corrected vision of 20/30 or worse in at least one eye and were deemed competent to answer the required questions. Patients were interviewed prospectively between December 1999 and March 2000 during a normal 30-minute period needed for pharmacologic mydriasis to occur. Demographic, clinical (including Snellen visual acuity) and time trade-off utility information was collected through chart review and standardized interview. Patients who completed the interview successfully were called back 28 days later for follow-up.Results: Of the 138 eligible patients 112 (81.2%) completed the initial interview. Of the 112, 96 (85.7%) completed the second interview. Half of the respondents were women, and all but one respondent were white. The mean age was 65.3 years. The primary reasons for visual loss included diabetic retinopathy (59 patients [61.4%]) and age-related macular degeneration (14 patients [14.6%]). The intraclass correlation coefficient between the initial and follow-up visual utilities was 0.7634 (95% confidence interval 0.6655-0.8355).Interpretation: Our results show excellent reliability of the time trade-off technique of utility assessment in patients with ocular diseases of the retina.

  DOI：

  10.1016/s0008-4182(01)80041-7

文献信息

• TRANSPARENT COMPOSITION WITH SOLUBLE SCALP HEALTH ACTIVE
  申请人：The Procter & Gamble Company

  公开号：US20210186839A1

  公开（公告）日：2021-06-24

  The present invention is directed to a personal care composition comprising from about 12% to about 25% of one or more surfactants; from about 0.01% to 10% of one or more soluble scalp health active; from about 0.1% to about 4% of a thickening polymer wherein the thickening polymer is selected from the group consisting of homopolymers based on acrylic acid, methacrylic acid or other related derivatives, alkali swellable and hydrophobically-modified alkali swellable acrylic copolymers or methacrylate copolymers, soluble crosslinked acrylic polymers, associative polymeric thickeners and mixtures thereof; from 0.01% to 0.8% of a cationic polymer; wherein the personal care composition has a pH of about 4.5 to about 6 and wherein the personal care composition has a Haze value less than or equal to 25.
• [EN] SYNTHESIS OF CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS<br/>[FR] SYNTHÈSE DE DÉRIVÉS DE CARBOXAMIDE CYCLOHEXANE UTILES COMME AGENTS SENSORIELS DANS DES PRODUITS DE CONSOMMATION
  申请人：PROCTER & GAMBLE

  公开号：WO2017070418A1

  公开（公告）日：2017-04-27

  Synthesis methods to produce a series of carboxamides built off of an (S)-2-amino acid backbone or an (R)-2-amino acid backbone, depending upon the desired diastereomer of the end product.